Fierce Biotech April 4, 2024
The Federal Trade Commission is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire the neuromodulation developer Axonics, a move that could push back the closing of the deal.
In a filing this week with the Securities and Exchange Commission, Boston Scientific said that both it and Axonics received calls for additional information from the FTC. Officially known as a “second request” in the government watchdog’s acquisition review process, the move can extend certain waiting periods required under antitrust law.
Boston Scientific and Axonics said they plan to respond promptly to the FTC’s requests. While the deal had initially been slated for closure during the first half of this year—back when it was announced in January, during...
Today's Sponsors
Today's Sponsor